Bicara Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Bicara Therapeutics, Inc. | BCAX - NASDAQ |
$16.00-$18.00 | $18.00 | $26.25 | 17.5 million | 9/13/2024 |
| Morgan Stanley, TD Cowen, Cantor, Stifel | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-08-22 Terms Added 2024-09-06 Amended Prospectus 2024-09-11 | ||||||
Bicara Therapeutics, Inc. Quote & Chart - Click for current quote - BCAX
IPO Boutique aggregates information on public companies and private companies, such as "BCAX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Bicara Therapeutics, Inc. (adapted from Bicara Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "BCAX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.